Loading patent…
AssigneeShanghai Nk Celltech Co., Ltd.
InventorsTing WANG, Yingli ZHOU, Cai ZHANG, Minhua CHEN
Estimating the term…
Provided is a transgenic recombinant immune cell specifically targeting a tumor. The recombinant immune cell includes a chimeric polypeptide and a chimeric antigen receptor. The chimeric polypeptide includes a first extracellular region having an activity of binding to HLA-G protein, a first transmembrane region, and a first intracellular region. The N-terminus of the first transmembrane region is linked to the C-terminus of the first extracellular region. The N-terminus of the first intracellular region is linked to the C-terminus of the first transmembrane region. The first transmembrane region includes a transmembrane region of Xenopus tropicalis Notch receptor protein. The chimeric antigen receptor does not have an HLA-G protein-binding activity.
A chimeric polypeptide, comprising:
A second nucleic acid molecule, comprising a first nucleic acid fragment and a second nucleic acid fragment, the 3′ end of the first nucleic acid fragment being linked to the 5′ end of the second nucleic acid fragment,
Dependencies are inferred from the claim text.